Allergology and Immunology, Department of Dermatology and Allergology, Charité - University Medical Center Berlin, Berlin, Germany.
J Dtsch Dermatol Ges. 2020 Oct;18(10):1085-1092. doi: 10.1111/ddg.14175. Epub 2020 Jul 14.
Atopic dermatitis (AD) is a frequent, chronic remittent skin disease. The pathophysiology of AD has been increasingly understood within the last years, which may help to identify different endotypes suitable for defined therapies in the future. A patient-oriented therapy considers phenotypical features in addition to genetic and biological markers. The most recent developments in biologics and small-molecule drugs for AD treatment are presented in this article. These molecules, if approved, could change the perspectives for future therapies. Dupilumab is the first approved biologic for the treatment of moderate to severe atopic dermatitis in adolescence and adulthood and has led to a significant improvement in the treatment of this chronic disease. In the present article we present real-life data on the efficacy of dupilumab in adult dermatitis patients. We also discuss other data relevant to the use of dupilumab, and address open questions important for the standard care of atopic dermatitis patients.
特应性皮炎（AD）是一种常见的、慢性复发性皮肤病。近年来，AD 的病理生理学已得到更深入的了解，这可能有助于确定未来适合特定治疗的不同表型。以患者为中心的治疗方法除了考虑遗传和生物学标志物外，还考虑表型特征。本文介绍了 AD 治疗中生物制剂和小分子药物的最新进展。如果这些药物获得批准，可能会改变未来治疗的前景。度普利尤单抗是首个获批用于治疗青少年和成人中重度特应性皮炎的生物制剂，它显著改善了这种慢性疾病的治疗效果。在本文中，我们提供了度普利尤单抗治疗成人特应性皮炎患者的真实疗效数据。我们还讨论了与度普利尤单抗使用相关的其他数据，并探讨了特应性皮炎患者标准护理中重要的未解决问题。
